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Abstract Self-monitoring of blood glucose (SMBG) is a
core component of diabetes management. However, the
International Diabetes Federation recommends that SMBG
be performed in a structured manner and that the data are
accurately interpreted and used to take appropriate thera-
peutic actions. We designed a study to evaluate the impact
of structured SMBG on glycemic control in non-insulin-
treated type 2 diabetes (T2DM) patients. The Prospective,
Randomized Trial on Intensive SMBG Management Added
Value in Non-insulin-Treated T2DM Patients (PRISMA) is
a 12-month, prospective, multicenter, open, parallel group,
randomized, and controlled trial to evaluate the added
value of an intensive, structured SMBG regimen in T2DM
patients treated with oral agents and/or diet. One thousand
patients (500 per arm) will be enrolled at 39 clinical sites in
Italy. Eligible patients will be randomized to the intensive
structured monitoring (ISM) group or the active control
(AC) group, with a glycosylated hemoglobin (HbA1c)
target of \7.0%. Intervention will comprise (1) structured
SMBG (4-point daily glucose profiles on 3 days per week
[ISM]; discretionary, unstructured SMBG [AC]); (2) com-
prehensive patient education (both groups); and (3) clini-
cian’s adjustment of diabetes medications using an algorithm
targeting SMBG levels, HbA1c and hypoglycemia (ISM) or
HbA1c and hypoglycemia (AC). The intervention and trial
design build upon previous research by emphasizing
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appropriate and collaborative use of SMBG by both patients
and physicians. Utilization of per protocol and intent-to-treat
analyses facilitates assessment of the intervention. Inclusion
of multiple dependent variables allows us to assess the
broader impact of the intervention, including changes in
patient and physician attitudes and behaviors. ClinicalTri-
als.gov (NCT00643474).
Keywords Type 2 diabetes mellitus  Self-monitoring
of blood glucose  Randomized clinical trial  Patient
empowerment  Diabetes medication algorithm
Introduction
Type 2 diabetes is a growing, worldwide epidemic with
significant clinical, social, and financial costs associated
with the devastating microvascular and macrovascular
complications of poorly controlled diabetes. Large ran-
domized, controlled clinical trials, such as the Diabetes
Control and Complication Trial (DCCT) and the United
Kingdom Prospective Diabetes Study (UKPDS), have
demonstrated that tight glycemic control reduces the risk of
microvascular diabetic complications in both type 1 diabetes
(T1DM) [1, 2], and T2DM [3–5]. Furthermore, long-term
follow-up of the DCCT and UKPDS cohorts has shown the
so-called legacy effect (i.e., a long-lasting positive effect of
tight glucose control on diabetes complication), even if
glucose control tends to deteriorate [2, 4]. However, in
patients with a high cardiovascular risk, an intensive man-
agement of diabetes targeting normal glycated hemoglobin
(HbA1c) levels with the use of multiple diabetes medications
is associated with higher mortality than is a standard
approach targeting higher HbA1c levels [6, 7].
While elevated HbA1c levels are clearly linked with the
development and progression of diabetic complications, a
growing body of evidence suggests that excessive post-
prandial glycemic excursions may also be a significant risk
factor for both microvascular [8] and macrovascular dis-
ease [9–14]. In patients with impaired glucose tolerance or
T2DM post-challenge glucose and glycemic spikes are
more strongly associated with carotid intima-media thick-
ening than fasting glucose and HbA1c [12, 14]. Con-
versely, diabetes medications that limit post-prandial
glucose excursions have been shown to reduce the risk of
macrovascular disease [15–17]. Furthermore, in poorly
controlled, non-insulin-treated T2DM patients, Monnier
and colleagues [18] found a correlation between the pro-
duction of 8-iso prostaglandin F2 (8-iso PGF2a), a marker
of oxidative stress, and the magnitude of glucose fluctua-
tions, calculated as the mean amplitude of glucose excur-
sion (MAGE) [19]. This finding is important, given the
possible role of post-prandial hyperglycemia in the patho-
genesis atherosclerosis in patients with diabetes.
Unlike HbA1c measurement, which only presents an
assessment of mean glucose over a 2–3 month period,
SMBG detects intra-day glycemic variability, thus, pro-
viding valuable feedback on the impact of behavioral and
pharmacological interventions on blood glucose levels.
This information can assist clinicians in their therapeutic
decision making when adjustments are needed, and it can
increase patients’ understanding of their disease, reinforce
self-management practices, and enhance patient empow-
erment [20, 21].
SMBG is only useful, however, when the glucose data
are collected in a structured manner, accurately interpreted,
and utilized to take appropriate therapeutic actions. New
guidelines from the International Diabetes Federation
(IDF) recommend that structured SMBG be performed
over short periods of time, initially and periodically, in
order to obtain glucose profiles that are representative of
daily glucose excursions [20]. The aforementioned studies
regarding glycemic variability [12, 14–17] suggest that
SMBG should be performed with increased frequency to
monitor glycemic excursions in T2DM patients even if the
effect on HbA1c may be minimal. They also suggest that
the various therapeutic strategies now in use should be
evaluated for their potential to minimize glucose excursion,
as well as for their ability to reduce HbA1c.
Although the value and utility of SMBG has been
demonstrated in T1DM [1, 22] and insulin-treated T2DM
[23, 24], SMBG use in non-insulin-treated diabetes remains
somewhat controversial. Some studies have shown little or
no glycemic benefit associated when SMBG was unstruc-
tured and/or clinicians underutilized results [25–27];
however, inherent limitations in the design of these studies
has resulted in some questioning of the related findings in
terms of external validity [20, 28, 29]. In essence, these
studies were not designed to make use of SMBG to guide
patient’s self-management and medical care with the aim
of improving metabolic control. Of note, more recent
studies, which utilized structured glucose monitoring reg-
imens as an integral component of comprehensive treat-
ment interventions, have demonstrated that appropriate use
of SMBG facilitates therapy optimization and desired
behavioral changes, leading to improved clinical outcomes
[30–34].
With the aim of further addressing this issue, we
designed a 12-month, prospective, multicenter, open, par-
allel group, randomized, and controlled clinical trial to
evaluate the impact of structured SMBG on glycemic
control in non-insulin-treated T2DM patients. In this study,
the SMBG was used to generate information on glucose
levels at specific times during the day and to make use of
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this information in order to prompt appropriate therapeutic
actions by patients and clinicians.
Methods
The Prospective, Randomized Trial on Intensive SMBG
Management Added Value in Non-insulin-Treated T2DM
Patients (PRISMA) is a 12-month, prospective, multicen-
ter, open, parallel group, randomized, and controlled clin-
ical trial that was designed to evaluate the added value of
an intensive, structured SMBG regimen in T2DM patients
treated with oral agents and/or diet alone (Fig. 1).
Patients randomized to the experimental group (inten-
sive structured monitoring [ISM]) will be compared with
patients who perform discretionary, unstructured SMBG
(active control [AC]). Patients will be evaluated every
3 months with the same scales and measures over the
12-month study period. The study protocol, written in
compliance with the Good Clinical Practice and the Hel-
sinki Declaration [35], was first approved by the Ethics
Committee of the San Raffaele Scientific Institute in
Milano and then by the Ethics Committee of each partic-
ipating clinical site. The clinical trial was registered at
ClinicalTrials.gov (NCT00643474).
Study population
Participants will be recruited from 39 clinical sites in Italy,
including diabetes outpatient clinics affiliated with aca-
demic institutions and hospitals of the Italian National
Health Care System. Inclusion criteria are as follows: age
between C 35 and B75 years; non-insulin-treated T2DM
(with diagnosis ranging from 1 to 10 years prior to study
enrollment); treatment with diet and oral hypoglycemic
agents or diet only; HbA1c ranging from 7.0% to 9.0%
measured in the clinical site’s laboratory within 2 weeks
before the date of signature of the informed consent;
willingness to adhere to study procedures; ability and
willingness to perform SMBG regimen; and willingness to
sign the study informed consent. Exclusion criteria are as
follows: T1DM, gestational diabetes or secondary diabetes;
a history of insulin treatment for more than 7 consecutive
days; previous intensive SMBG management (systematic
or structured SMBG to adjust lifestyle or pharmacologic
therapy); impending complications of diabetes; clinically
significant, acute diseases (cardiovascular, gastrointestinal,
neurological, genitourinary, and hematological systems) or
severe uncontrolled hypertension (systolic blood pressure
[180 mm Hg; diastolic blood pressure [100 mm Hg);
serious diseases or limited life expectancy that would make
intensive glycemic control inappropriate; known pregnancy
or intention to become pregnant during the study; lactation;
inability to read or to write; and potentially poor adherence
to study procedures.
Intervention
The study intervention (Table 1) will last 12 months and
will comprise three key components: (1) structured SMBG;
(2) comprehensive patient education; and (3) clinician’s use
of a diabetes medication algorithm. Combining these three
components effectively addresses our study hypothesis.
Structured SMBG
A key component of the study intervention is utilization of
a structured SMBG regimen that requires patients to gen-
erate 4-point daily glucose monitoring profiles on 3 days
per week (2 working days, 1 weekend day). The mea-
surements will be taken before breakfast, before lunch (pre-
prandial), 2 h after lunch (post-prandial), and 5 h after
lunch but before dinner (post-absorptive phase). All
patients will complete one 3-day, 4-point glucose profile
during the assessment period. ISM patients will be
instructed to complete one 3-day, 4-point profile per week
during the course of the study. SMBG data will be down-
loaded to a PC through a wireless device (Accu-Chek
Smart-Pix system, Roche Diagnostics, S.p.A., Monza,
Italy) and analyzed using ad hoc software that provides
V0
screening
V1 (baseline)
randomization
V2 (3 months)
AC group
ISM group
Intervention: 12 months
V3 (6 months) V4 (9 months)
Fig. 1 Diagram of the
PRISMA study protocol
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easy-to-read summary statistics, which clinicians will use
in conjunction with HbA1c and hypoglycemia to adjust
diabetes medications (Fig. 2). AC patients will be
instructed to complete one 3-day, 4-point profile prior to
their 6- and 12-month visits to obtain data for comparison
with the ISM group; in the AC group, SMBG data will not
be downloaded from the glucometer, nor will be used to
make adjustment of diabetes medications, which will be
based exclusively on HbA1c and hypoglycemic events
(either self-reported or documented).
Table 1 Summary of the intervention for the ISM and AC groups
ISM group AC group
Measurements of capillary glucose at fixed times 12 Measurements per week for
1 year (i.e., 4-point daily profile,
3 times per week for 1 year)
12 Measurements during the week before V3
and V5 (i.e., 4-point daily profile, 3 times
during the week before V3 and V5)
Additional discretionary capillary glucose measurements 50 every 3 months 26 for one year
Standard educational program sessions Yes Yes
Structured SMBG data available to the patient to guide
lifestyle changes
Yes No
Structured SMBG data available to the investigator to
adjust diabetes medications
HbA1c and SMBG data HbA1c only
ISM intensive structured monitoring, AC active control, V3 visit 3, V5 visit 5, SMBG self-monitoring of blood glucose
Fig. 2 Data analysis system. The print-out of the Smart-Pix device is
organized in four boxes: Box 1 shows mean, standard deviation, and
number of glucose measurements during the previous 4 weeks, by
point of the daily profile presented as a bar graph; Box 2 shows mean
and number of glucose measurements during the previous 4 weeks
before breakfast and lunch and mean and number of post-prandial
glycemic excursion, each presented as a speed dial: the pointer in the
green zone indicates desirable values, in the yellow zone values that
requires attention, and in the red zone values that require corrective
action; the number of hypoglycemic episodes is reported in a dot that
changes color from green (no glucose value\70 mg/dl) to red when
blood glucose values \70 mg/dl are measured; Box 3 shows the low
blood glucose index (LBGI) and high blood glucose index (HBGI)
[40] and the average daily risk range (ADRR) [49] calculated on the
glucose values since the last visit and presented as a bar graph in
green color if in the desired range, in red if outside the desired range;
and Box 4 shows the suggested changes in diabetes medication
according to the algorithm presented in Fig. 3
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Comprehensive patient education
A commercially available educational program (Accu-
Chek eduCare, Roche Diagnostics, S.p.A., Monza, Italy)
will be used to provide standardized information to the
patients who are enrolled in the study. The program is
organized into subject-specific modules and includes charts
and other materials to support training sessions and patient
engagement. A basic session, covering nutrition, physical
activity, SMBG, and diabetes medications, will be pro-
vided to all enrolled patients at the beginning of the study
in order to avoid diabetes education differences between
the ISM and AC group. Patients will complete additional
modules of the educational program throughout the study.
The educational program will be provided to study par-
ticipants either by the investigator, the diabetes nurse, or
the dietician.
Diabetes medication algorithm
During the study visits, clinicians will prescribe diabetes
medication with the aim of reaching target HbA1c levels of
\7.0% [36]. For ISM patients, clinicians will use an
algorithm based on guidelines from international and
national scientific societies (American Diabetes Associa-
tion [ADA], European Association for the Study of Dia-
betes [EASD], International Diabetes Federation [IDF],
Societa` Italiana di Diabetologia [SID], and Associazione
Medici Diabetologi [AMD]) [37–39]. Incretin mimetics
and DPP-4 inhibitors were not available in Italy when the
PRISMA protocol was written and, therefore, were not
included in the diabetes medication algorithm. Over the
study period, exenatide, liraglutide, sitagliptin, vildagliptin,
and saxagliptin became available for the treatment of
patients with T2DM and investigators were notified that
those drugs could be used in PRISMA participants
according to the European Medicines Agency (EMA)
therapeutic indications.
The algorithm bases the changes in diabetes medications
(either type or dosage) on the mean fasting or pre-prandial
glucose, on the difference between post- and pre-prandial
glucose, and on hypoglycemic events (self-reported or
documented) (Fig. 3). However, clinicians will have the
option to make changes to the type or dosage of diabetes
medications according to their own clinical judgment.
Furthermore, clinicians will have the opportunity to use a
feature of the ad hoc software that suggests the appropriate
changes in diabetes medication according to the algorithm
(Fig. 2). In the AC group, where patients are not required
to perform any structured SMBG, the changes in diabetes
medications will be based exclusively on HbA1c levels and
hypoglycemic events (either self-reported or documented).
Adherence of care provider to the study protocol will
be enhanced by training sessions before recruitment of
If not treated with Metformin Metformin 
Mean fasting or pre-prandial 
blood glucose >110 mg/dl If treated with Metformin 
Intensify Metformin 
treatment to 2-2.5 g/day
If already treated with maximum 
dose of Metformin (or this is 
contraindicated or not tolerated)  
Add a 
Thiazolidinedione 
(TZD) up to the 
maximum dose 
If not treated with Repaglinide or a 
Sulfonylurea (SU) Add Repaglinide or SU 
Mean difference between post-
prandial and pre-prandial blood 
glucose >50 mg/dl 
If treated with Repaglinide or a SU 
Intensify Repaglinide 
or SU up to the 
maximally effective 
dose 
If already treated with maximum 
dose of Repaglinide or SU (or these 
are contraindicated or not tolerated) 
Acarbose or TZD 
according to their 
tolerability 
Reduce the dose of the 
SU by 50% 
or
More than 3 blood glucose 
values <70 mg/dl If treated with a SU Stop the SU 
or
A mean negative difference 
between post-prandial and pre-
prandial blood glucose values 
Switch from SU to 
Repaglinide 
Hypoglycemic episodes reported   Reduce the dose of Repaglinide by 50% 
or 
edinilgapeRpotS
If treated with Repaglinide
Fig. 3 Diabetes medication
algorithm. The diabetes
medication algorithm is based
on guidelines by international
and national scientific societies
[American Diabetes Association
(ADA), European Association
for the Study of Diabetes
(EASD), International Diabetes
Federation (IDF), Societa`
Italiana di Diabetologia (SID)
and Associazione Medici
Diabetologi (AMD)] [37–39]
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patients and throughout the study. Three investigator’s
meetings will be conducted during the study, and periodic
newsletters will be e-mailed to investigators encouraging
them to share knowledge and discuss study procedures.
Primary and secondary endpoints
Two primary endpoints will be tested subsequently,
according to the following hierarchical order: (1) the
change in HbA1c levels from baseline to visit 5; and (2) the
percentage of participants reaching or maintaining the risk
target (Low Blood Glucose Index (LBGI) B 2.5 together
with High Blood Glucose Index (HBGI) B 5) from baseline
to visit 5. HbA1c will be measured by a central laboratory
(Laboraf Diagnostica e Ricerca, Milano, Italy) using the
Variant II testing systems (Bio-Rad, Segrate, Italy) on
whole blood samples kept frozen at -80 C until assayed.
This method is certified by the National Glycohemoglobin
Standardization Program as traceable to the method used in
the DCCT.
LBGI and HBGI are computed using capillary glucose
values according to Kovatchev et al. [40]. LBGI and HBGI
have been shown to predict the risk of hypoglycemia and
hyperglycemia, respectively [41–43].
The primary endpoints will be managed using a
‘‘sequence of comparisons’’ approach: step 1—shows that
the ISM is superior to the AC group in the first co-primary
endpoint; and step 2—shows that the ISM is superior to the
AC in the second co-primary endpoint. Step 1 is based on a
two-sided test with an alpha of 5%, and a significant result
in the relevant direction is required to continue with step 2,
which is also based on a two-sided test with an alpha of 5%.
Secondary endpoints in both study groups include
changes in HBGI and LBGI, changes in SMBG frequency,
changes in diabetes therapy (either type of medication or
dosage), frequency and severity of hypoglycemic episodes,
and changes in blood pressure, estimated glomerular fil-
tration rate (eGFR, computed using a creatinine-based
formula) [44] lipid profile, and body mass index (BMI).
Additional secondary endpoints are the changes of the
scores of two questionnaires: (1) a diabetes-specific quality
of life questionnaire, which is a modification of the dia-
betes quality of life questionnaire used in the DCCT [45].
The original DCCT questionnaire was translated into Ital-
ian, modified for being used in patients with T2DM, and
validated [46]; and (2) the diabetes-specific locus of control
questionnaire [47] translated into Italian [48]. Study-related
adverse events and diabetes-related adverse events will be
recorded and compared in the two groups.
Additional secondary endpoints will be analyzed in the
ISM group. These will include inter-visit changes in mean
blood glucose (to assess glycemic exposure), blood glucose
standard deviation (to assess glycemic variability), average
fasting, pre-prandial, post-prandial, and post-absorptive
phase glucose levels. The average difference between pre-
prandial and post-prandial values within the same day and
changes in lifestyle will also be analyzed. Correlations
between patient age, diabetes duration, HbA1c, LBGI,
HBGI, average daily risk range (ADRR) [49], mean blood
glucose, standard deviation, and lipid levels will also be
performed.
Changes in urinary 8-iso PGF2a, an index of oxidative
stress, will be measured and analyzed for the study par-
ticipants of the six clinical sites that agreed to collect 24-h
urine samples at visit 1 and visit 5 [24]. One hundred
microliters of a 0.005% butylhydroxytoluene solution in
ethanol will be added to 10 milliliter of urine for each 24-h
urine collection. Samples will be stored at -80 C until
shipment in dry ice to the central laboratory. Urinary 8-iso
PGF2a will be measured using an enzymatic immunoassay
(Cayman Chemical Company, Ann Arbor, MI, USA) [50].
Sample size
Five hundred participants in each group (1,000 total) will be
required to have an approximate 90% probability of
detecting as significant (at the two-sided 5% level) a 0.3%
difference between the ISM and AC group in the mean
HbA1c change at visit 5 compared to baseline, with an
assumed standard deviation of 1.25% and a loss to follow-
up of 25%. This sample size will also provide 85% power to
show an 11% difference between the two groups in per-
centage of subjects reaching or maintaining the risk target
(LBGI B2.5 and HBGI B5), considering 50% of subjects
arriving to target in the standard group.
Study procedures
The duration of the intervention is 12 months, with patient
visits occurring during the assessment period at baseline
(visit 1) and at months 3, 6, 9, and 12 (visit 2, 3, 4, and 5,
respectively). The study will be managed by a certified
clinical research organization (CROM, Verona, Italy).
Assessment period
During the assessment period—less than 15 days prior to
the baseline visit—clinicians will describe the study in
details to prospective participants, obtain written informed
consent, record demographics, collect relevant medical
history/lifestyle information, document all current medi-
cations, perform physical examinations, measure and
record weight, height, blood pressure, heart rate, compute
body mass index (BMI), and collect laboratory samples to
measure lipid levels and serum creatinine. Urine for the
measurement of 8-iso PGF2a will be collected in patients
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from the six clinical sites that agreed to participate in this
ancillary study.
All eligible patients will be asked to complete the dia-
betes-specific quality of life questionnaire and the diabetes-
specific locus of control questionnaire. They will receive a
blood glucose meter (Accu-Chek Aviva, Roche Diag-
nostics, Indianapolis, IN, USA) and 12 test strips to obtain
a 4-point daily glucose profile 3 times in 1 week, two
during working days and one during the weekend, and they
will be scheduled to attend the basic session of the com-
prehensive educational program.
First visit
At the first visit, investigators will download SMBG data
from the blood glucose meters using an automated down-
loading device. All serious and non-serious adverse events
will be recorded. Eligible patients will then be randomized to
the ISM or AC group. A computer generated randomization
list prepared by a statistician and unknown to the investi-
gators at the clinical sites will be used. The randomization
code was developed by a statistician of the clinical research
organization managing the study and will be unknown to the
investigators at the clinical sites. A computer random num-
ber generator was used to select random permuted blocks of
size 4. Randomization will be stratified by the diabetes
treatment regimens of participants at the time of enrollment
(diet only, or diet plus diabetes medications). Each clinical
site will receive two sets of sealed, sequentially numbered,
opaque envelopes containing the allocation information that
were prepared by the personnel of the clinical research
organization managing the trial. The investigators will be
trained to write the name of the patient to be randomized on
the envelope with the lowest sequence number of the
appropriate set (diet only or diet plus diabetes medications)
and then open the envelope and discuss treatment allocation
with the patient. Investigators and study participants will not
be blinded to group assignment. Statisticians analyzing the
data and personnel at the central laboratory measuring
HbA1c will be blinded to group assignment.
ISM patients will receive 150 test strips to obtain the
requested glucose profiles and an additional 50 test strips for
discretionary use (in case of hypoglycemia and/or at any
time, they feel the need to monitor their blood glucose lev-
els). They will also receive additional instructions on how to
interpret SMBG data and a dedicated diary listing the
assigned glycemic targets: \110 mg/dL for fasting and
before-lunch values and \50 mg/dL difference between
post-prandial and pre-prandial glucose levels) and sugges-
tions on how to reach them. Suggestions will be in the form of
‘‘cheat lists’’ with appropriate lifestyle changes in response
to real life situations (e.g., too high post-prandial glycemic
excursion or a low pre-prandial glucose value, etc.).
AC patients will receive 24 test strips to obtain the
requested glucose profiles and an additional 26 test strips
for discretionary use. No instruction will be provided to AC
patients regarding timing and frequency of testing.
Blood samples for the measurement of HbA1c by the
central laboratory will be collected, frozen at -80C, and
stored until shipment in dry ice. All participants will be made
aware of their risk of hypoglycemia, based on the diabetes
medications they have been prescribed. After resolving any
hypoglycemic event, patients will be asked to record the
glucose value in an ad hoc diary and contact the center of
case of additional hypoglycemic episodes close in time.
Follow-up visits
At each follow-up visit (months 3, 6, 9, and 12), investi-
gators will perform physical examinations; measure and
record BMI, blood pressure, and heart rate; collect blood
samples for HbA1c measurements; and record changes in
diabetes treatment. With patients randomized to the ISM
group, investigators will review and discuss the patient’s
diary, record changes in diet and physical activity, and
review structured SMBG measurements. For patients in the
ISM group, investigators will have the option to use the
defined algorithm for adjusting diabetes medications based
on the downloaded SMBG data; however, they will be
allowed to make adjustments according to their clinical
judgment. In the AC group, SMBG data will not be used to
make adjustments of diabetes medications, which will be
based exclusively on HbA1c and hypoglycemic events
(either self-reported or documented).
ISM patients will receive 200 test strips at each follow-
up visit for the requested glucose profiles (150 strips) and
additional testing (50 strips). AC patients will receive
‘‘memo cards’’ at month 3 and 9 visits, reminding them to
complete their 3-day, 4-point glucose profiles prior to
month 6 and 12 visits, when data collected in the meters
will be downloaded. All patients will be offered additional
education sessions from the standardized education pro-
gram throughout the study.
Statistical analysis
Primary and secondary endpoints will be analyzed for the
intent-to-treat (ITT) population, which consists of all ran-
domized patients who have a baseline and at least one post-
baseline assessment. Only the primary endpoint will be
analyzed for the per protocol (PP) population, which con-
sists of all randomized patients from the ITT population
who complete the study without major protocol violations
and who are compliant with the SMBG regimen (i.e., for
participant in the ISM group at least 80% of the expected
structured capillary glucose measurements; for the AC
Acta Diabetol (2013) 50:663–672 669
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group \200 unstructured discretionary capillary glucose
measurements).
All statistical analyses and data processing will be per-
formed using SAS Software (version 9.02, TS level
02M0) on a Windows 2000/XP Pro operating system.
Descriptive statistics will be provided in summary tables
by group according to the type of variable summarized.
Standard quantitative statistics (N, mean, standard devia-
tion, median, minimum, and maximum) will be presented
for quantitative criteria. Frequency distribution (number of
non-missing observations [N] and percentages [%]) will be
presented for qualitative criteria.
The analysis of the first co-primary endpoint (i.e., the
mean change in HbA1c levels from baseline to visit 5) will
be analyzed using the SAS PROC MIXED procedure and
will be based on a mixed linear model with randomized
group, center, visit, and the randomized-group-by-visit
interaction as fixed effects and baseline as covariate. An
unstructured variance–covariance matrix will be used to
model the correlation within each patient and between the
four repeated measurements (i.e., over the post-baseline
visits). Maximum likelihood estimates and 95% confidence
intervals of the mean difference between randomized
groups at 12 months will be calculated using the Newton–
Raphson algorithm implemented in the SAS Proc Mixed
Procedure. A two-sided test with a P value B0.05 will be
considered statistically significant.
The interaction between randomized group and center
will be assessed. A two-sided p value B0.10 will be
considered statistically significant for the test of interac-
tion between randomized group and center. If a statisti-
cally significant interaction is observed, efforts will be
made to determine whether and how the interaction may
affect the comparisons between randomized groups.
Taking into account that maximum likelihood estimates
have less bias than single imputation methods (e.g.,
LOCF) for missing informative and are, by definition,
unbiased under a missing completely at random (MCAR)
and a missing at random (MAR) mechanism of ‘‘miss-
ingness,’’ the mixed linear model described above repre-
sents an ideal choice for handling missing data and
correcting for the bias potentially caused by drop-out
participants in this study [51].
The analysis of the second co-primary endpoint (i.e., the
percentage of subjects reaching or maintaining the risk
target at visit 5 compared to baseline) will be analyzed
using the SAS PROC FREQ procedure and will be based
on the Cochran–Mantel–Haenszel test controlling for
clinical site effects.
Secondary endpoints will be analyzed according to the
type of variable. Summary statistics and 95% confidence
intervals will be calculated for mean changes (continuous
variables) and for risk differences (categorical variables).
Discussion
Diabetes is a growing, worldwide epidemic with significant
associated clinical, social, and economic costs. It is critical
that healthcare resources committed to diabetes manage-
ment are applied both effectively and efficiently.
The benefits of SMBG have been demonstrated in type 1
diabetes (T1DM) and insulin-treated type 2 diabetes
(T2DM) [1, 2, 23]; however, findings from studies in non-
insulin-treated T2DM have been inconsistent. In studies that
utilized random or low-intensity blood glucose monitoring
regimens and/or where the data generated were not used to
make treatment decisions, SMBG showed little or no benefit
[25–27]. More recent studies, however, have shown a sig-
nificant benefit when SMBG is structured in a manner that
yields easily discernable blood glucose patterns, and when
those data are used to make appropriate therapeutic changes
in lifestyle or diabetes medications [30–34].
Our study was designed to test the optimal use of SMBG
to improve HbA1c and minimize glycemic excursions.
With the inclusion criteria of an HbA1c from 7 to 9% we
expect to capture participants who are representative of the
Italian patient population attending a diabetes clinic and
not meeting the target of good glycemic control [52]. It is
important to note that our intervention emphasizes appro-
priate utilization of SMBG data by both patients and cli-
nicians, focusing on the value of SMBG as a tool that
enhances patients’ understanding of their disease, supports
the modification of patient behavior toward a healthier
lifestyle, and guides and supports therapeutic changes by
both clinicians and patients. Utilization of PP analyses in
conjunction with ITT will enable us to both identify
obstacles to adherence and more fully assess the efficacy of
the intervention. Inclusion of multiple dependent variables
will allow us to assess the broader impact of the inter-
vention, including changes in patient and physician atti-
tudes and behaviors. Patient recruitment for the PRISMA
study started in April 2008 and was completed in May
2010; results will be available in 2012.
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